Trastuzumab NEW
| Price | $157 | $546 | $689 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Trastuzumab | CAS No.: 180288-69-1 |
| Purity: 99.50% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Trastuzumab |
| Description | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. |
| In vitro | METHODS: Human breast cancer cells BT-474 were treated with Trastuzumab (0.01-10 μg/mL) for 72 h. Cell viability was determined by MTS Assay. RESULTS: The antiproliferative effect of Trastuzumab was observed at concentrations as low as 0.5 μg/mL, with a stabilizing level of approximately 10 μg/mL.[1] METHODS: CHO-K6, CHO-EGFR and CHO-HER3 cells were treated with Trastuzumab (0.1-10 μg/mL) for 5-60 min, and binding to HER receptors was detected by Immunofluorescence. RESULTS: Trastuzumab binds only to HER2, but not to EGFR and HER3. [2] |
| In vivo | METHODS: To test the in vivo antitumor activity, Trastuzumab (5 μg/g) was administered intraperitoneally once a week for seven doses to nude mice harboring human mammary carcinoma tumor JIMT-1. RESULTS: Trastuzumab had a significant inhibitory effect on tumor growth on days 21-56. After stopping administration, tumors began to grow in two nude mice whose tumors were palpable earlier. [3] |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| Keywords | EGFR | Trastuzumab | Anti-Human HER2, Humanized Antibody | Epidermal growth factor receptor | HER1 | inhibit | ErbB-1 | Inhibitor |
| Inhibitors Related | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Afatinib Dimaleate | Erlotinib hydrochloride | Erlotinib | Neratinib | Chalcone | Osimertinib mesylate | Genistein | Khellin | Gefitinib |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1G |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2023-01-10 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-02 | |
| $0.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 | |
| $7.00/1KG |
VIP6Y
|
Career Henan Chemical Co
|
2020-01-02 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY